| Drug / Therapy | lecanemab (Leqembi) |
| Indication | early AD subcutaneous sNDA |
| Decision Type | PDUFA |
| Conditions | early AD subcutaneous sNDA |
| Interventions | lecanemab (Leqembi) |
Biogen Inc (BIIB) operates in the Neuroscience sector. The current BTS Score is 36 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for lecanemab (Leqembi) by Biogen Inc (BIIB) is scheduled for December 10, 2026. This is the target date for the FDA to make a decision on this application.
lecanemab (Leqembi) is being developed by Biogen Inc for the treatment of early AD subcutaneous sNDA. It is under FDA review.
If lecanemab (Leqembi) receives FDA approval, Biogen Inc (BIIB) would be able to market the drug in the United States for early AD subcutaneous sNDA. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for BIIB on DilutionWatch at dilutionwatch.com/stock/BIIB.html.
You can view the full BiotechSigns company profile for Biogen Inc (BIIB) at biotechsign.com/app/company/BIIB, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.